These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 24459693)

  • 1. Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft.
    Shaikh IM; Tan KB; Chaudhury A; Liu Y; Tan BJ; Tan BM; Chiu GN
    J Control Release; 2013 Dec; 172(3):852-61. PubMed ID: 24459693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-tumor activity of liposome encapsulated fluoroorotic acid as a single agent and in combination with liposome irinotecan.
    Riviere K; Kieler-Ferguson HM; Jerger K; Szoka FC
    J Control Release; 2011 Aug; 153(3):288-96. PubMed ID: 21600250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Encapsulation of doxorubicin into thermosensitive liposomes via complexation with the transition metal manganese.
    Chiu GN; Abraham SA; Ickenstein LM; Ng R; Karlsson G; Edwards K; Wasan EK; Bally MB
    J Control Release; 2005 May; 104(2):271-88. PubMed ID: 15907579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective co-encapsulation of doxorubicin and irinotecan for synergistic therapy using liposomes prepared with triethylammonium sucrose octasulfate as drug trapping agent.
    Liu J; Chi D; Pan S; Zhao L; Wang X; Wang D; Wang Y
    Int J Pharm; 2019 Feb; 557():264-272. PubMed ID: 30599233
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formation of transition metal-doxorubicin complexes inside liposomes.
    Abraham SA; Edwards K; Karlsson G; MacIntosh S; Mayer LD; McKenzie C; Bally MB
    Biochim Biophys Acta; 2002 Sep; 1565(1):41-54. PubMed ID: 12225851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Palmitoyl ascorbate and doxorubicin co-encapsulated liposome for synergistic anticancer therapy.
    Yang Y; Lu X; Liu Q; Dai Y; Zhu X; Wen Y; Xu J; Lu Y; Zhao D; Chen X; Li N
    Eur J Pharm Sci; 2017 Jul; 105():219-229. PubMed ID: 28526602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal irinotecan: formulation development and therapeutic assessment in murine xenograft models of colorectal cancer.
    Messerer CL; Ramsay EC; Waterhouse D; Ng R; Simms EM; Harasym N; Tardi P; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Oct; 10(19):6638-49. PubMed ID: 15475454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo.
    Tardi PG; Gallagher RC; Johnstone S; Harasym N; Webb M; Bally MB; Mayer LD
    Biochim Biophys Acta; 2007 Mar; 1768(3):678-87. PubMed ID: 17208196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposome formulation of co-encapsulated vincristine and quercetin enhanced antitumor activity in a trastuzumab-insensitive breast tumor xenograft model.
    Wong MY; Chiu GN
    Nanomedicine; 2011 Dec; 7(6):834-40. PubMed ID: 21371568
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading.
    Abraham SA; McKenzie C; Masin D; Ng R; Harasym TO; Mayer LD; Bally MB
    Clin Cancer Res; 2004 Jan; 10(2):728-38. PubMed ID: 14760096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel sulfobutyl ether cyclodextrin gradient leads to highly active liposomal irinotecan formulation.
    Li C; Cui J; Wang C; Li Y; Zhang L; Xiu X; Li Y; Wei N; Zhang L; Wang P
    J Pharm Pharmacol; 2011 Jun; 63(6):765-73. PubMed ID: 21585373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topophore C: a liposomal nanoparticle formulation of topotecan for treatment of ovarian cancer.
    Patankar NA; Waterhouse D; Strutt D; Anantha M; Bally MB
    Invest New Drugs; 2013 Feb; 31(1):46-58. PubMed ID: 22615060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased preclinical efficacy of irinotecan and floxuridine coencapsulated inside liposomes is associated with tumor delivery of synergistic drug ratios.
    Harasym TO; Tardi PG; Harasym NL; Harvie P; Johnstone SA; Mayer LD
    Oncol Res; 2007; 16(8):361-74. PubMed ID: 17913044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel liposomal irinotecan formulation with significant anti-tumour activity: use of the divalent cation ionophore A23187 and copper-containing liposomes to improve drug retention.
    Ramsay E; Alnajim J; Anantha M; Zastre J; Yan H; Webb M; Waterhouse D; Bally M
    Eur J Pharm Biopharm; 2008 Mar; 68(3):607-17. PubMed ID: 17904831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes.
    Vaage J; Donovan D; Mayhew E; Abra R; Huang A
    Cancer; 1993 Dec; 72(12):3671-5. PubMed ID: 8252484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release.
    Li C; Cui J; Li Y; Wang C; Li Y; Zhang L; Zhang L; Guo W; Wang J; Zhang H; Hao Y; Wang Y
    Eur J Pharm Sci; 2008 Aug; 34(4-5):333-44. PubMed ID: 18573336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engineering of a lipid-polymer nanoarchitectural platform for highly effective combination therapy of doxorubicin and irinotecan.
    Ramasamy T; Ruttala HB; Choi JY; Tran TH; Kim JH; Ku SK; Choi HG; Yong CS; Kim JO
    Chem Commun (Camb); 2015 Apr; 51(26):5758-61. PubMed ID: 25720556
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of the transition metal copper and the ionophore A23187 in the development of Irinophore C™.
    Patankar N; Anantha M; Ramsay E; Waterhouse D; Bally M
    Pharm Res; 2011 Apr; 28(4):848-57. PubMed ID: 21181548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model.
    Harrington KJ; Rowlinson-Busza G; Syrigos KN; Vile RG; Uster PS; Peters AM; Stewart JS
    Clin Cancer Res; 2000 Dec; 6(12):4939-49. PubMed ID: 11156255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Copper-topotecan complexation mediates drug accumulation into liposomes.
    Taggar AS; Alnajim J; Anantha M; Thomas A; Webb M; Ramsay E; Bally MB
    J Control Release; 2006 Aug; 114(1):78-88. PubMed ID: 16842880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.